التفاصيل البيبلوغرافية
| العنوان: |
F-18-FET and F-18-choline PET/CT in Patients with Newly Diagnosed Low-Grade Gliomas: A Pilot Study. |
| المؤلفون: |
Hodolič, Marina, Krpan, Ana Mišir, Golubić, Anja-Tea, Žuvić, Marijan, Baučić, Maja, Mrak, Goran, Nemir, Jakob, Huić, Dražen |
| المصدر: |
Nuclear Medicine Seminars; 2019 Supplement 1, Vol. 5, p16-16, 1/2p |
| مصطلحات موضوعية: |
FLUORODEOXYGLUCOSE F18, POSITRON emission tomography, GLIOMA treatment, BRAIN tumor diagnosis, RADIOPHARMACEUTICALS |
| مستخلص: |
Aim: Low grade gliomas (LGG) account for app. 15% of all gliomas. Most LGG gradually evolve into high grade tumours. Method: fMRI results are often inconclusive, ambiguous or indeterminate. The definitive diagnosis can be achieved by brain biopsy, which is invasive, inaccessible, associated with sampling errors. Results: O-[2-(F-18)-fluoromethyl]-L-tyrosine (F-18-FET) has been recently approved in EU as a positron emission tomography (PET) radiopharmaceutical for characterisation of brain lesions suggestive of gliomas. F-18-FET has advantage of displaying a high tumour-tobackground ratio and not accumulating in inflammatory lesions. Because of low uptake in normal brain parenchyma, fluoromethyl-(F-18)-dimethyl- 2-hydroxyethyl-ammonium chloride F-18-fluorocholine (FCH) has proven to be a good alternative in centres where F-18-FET is not available. No study has been published on the use of F-18-FCH and F-18-FET in primary diagnosis of LGG. The objective of this pilot study was to determine accuracy of primary diagnosis of LGG with choosing the appropriate PET radiopharmaceutical. This pilot study comprised 8 patients (age 37-80 years) with suspected LGG, diagnosed with 3TMRI and/or stereotactic-brain-biopsy. After fMRI and/ or stereotactic-brain-biopsy all patients underwent F-18-FCH and F-18-FET PET/computerized tomography (CT) within one week. Patients underwent surgery within one to two weeks after PET/CT. Pathohistological results were compared with F-18-FCH and F-18-FET PET/CT findings. Seven out of eight patients had full imaging diagnostics with final pathohistological findings after surgery. Five of them were fMRI and pathohistologically diagnosed as LGG: four were positive on F-18-FET [standardized uptake value (SUVmax): 1.7; 2; 2.8 and 1.8] and negative on F-18-FCH PET/CT. One patient with pathohistologically proved LGG had negative F-18-FET and negative F-18-FCH PET/CT. Two patients diagnosed as LGG on MRI were confirmed as glioblastoma multiforme after surgery: both of them were positive on F-18-FCH (SUVmax 3.9 and 1.6) and F-18-FET (SUVmax 3.1 and 3) PET/CT. The last patient who entered this study had negative F-18-FCH and positive F-18-FET (SUVmax 1.5) PET/CT but has no final pathohistological diagnosis yet. Conclusion: Preliminary results based on a small number of patients showed that appropriate radiopharmaceutical should be chosen before performing PET/CT in patients with newly diagnosed LGG. F-18-FCH seems not to be appropriate tracer in patients with newly diagnosed LGG. Both tracers, F-18-FCH and F-18-FET, seems to be appropriate in primary diagnosis of high grade gliomas. The study is ongoing. [ABSTRACT FROM AUTHOR] |
|
Copyright of Nuclear Medicine Seminars is the property of Galenos Yayinevi Tic. LTD. STI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
